Galmed Pharmaceuticals Company Profile (NASDAQ:GLMD)

Analyst Ratings

Consensus Ratings for Galmed Pharmaceuticals (NASDAQ:GLMD) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.17 (354.19% upside)

Analysts' Ratings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2015MLV & Co.Reiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015SunTrust Banks Inc.Lower Price TargetBuy$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.37)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.32)($0.32)
Q2 20163($0.41)($0.26)($0.35)
Q3 20163($0.44)($0.28)($0.37)
Q4 20163($0.39)($0.30)($0.34)
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateHeadline
07/22/16 07:09 AMEarnings Focus and Crowd Sourced Sentiment Review for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - TGP
07/21/16 04:26 PMTracking Analyst Ratings and Target Projections for: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph
07/21/16 04:26 PMGalmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Sellers Increased By 8.56% Their Shorts - Consumer Eagle
07/20/16 07:07 AMGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 04:28 PMGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Increased 2.56%: Cognizant Technology Solutions Corporation ... - KC Register
07/18/16 04:28 PMTrading Performance and Target Watch for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph
07/18/16 04:28 PMWere Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) This Week? - Consumer Eagle
07/14/16 04:21 PMCould Galmed Pharmaceuticals Ltd Go Down? The Stock Formed Bearish Double Bottom Chart Pattern - Consumer Eagle
07/14/16 04:21 PMCrowd Rating and Earnings Recap for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Telanagana Press
07/14/16 04:21 PMBrokers Issue Average Price Target Of 19.00 On Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard
07/14/16 04:21 PMGalmed Pharmaceuticals Ltd. (GLMD) Updated Price Targets - FTSE News
07/13/16 07:06 AMGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 08:59 AMAre Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) After Last Week? - Press Telegraph
07/07/16 07:03 AMBroker Outlook For Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard
07/05/16 08:56 AMBroker Outlook For The Week Ahead Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard
07/04/16 09:09 AMDoes This Provide a Reason to Sell Galmed Pharmaceuticals Ltd? The Stock Has Formed Bearish Double Bottom - Press Telegraph
07/01/16 07:01 AMGalmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration - StreetInsider.com
06/30/16 04:31 PMGalmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration
06/30/16 07:21 AMGalmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome - [at noodls] - TEL AVIV, Israel, June 30, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
06/28/16 09:10 PMGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 09:10 PMShare Update and Earnings Review for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph
06/28/16 04:08 PMEquity Research and Technical Review on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph
06/27/16 08:40 AMGalmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Short Interest Increased By 54.4% - Press Telegraph
06/23/16 07:07 AMNew Broker Ratings For Galmed Pharmaceuticals Ltd. (GLMD) - FTSE News
06/20/16 10:29 AMGalmed Pharmaceuticals Ltd. (GLMD) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 04:14 PMRecently Issued Stock Ratings For Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard
06/08/16 10:23 PMGalmed Pharma Reports Expansion of Ongoing Phase IIb ARREST Study to China
06/08/16 04:55 AMALDX Expects Data In Q3, CATB Tumbles On Study Data, Teva Gets FDA Panel Nod
06/07/16 10:04 AMGalmed Pharmaceuticals Says Ongoing Phase IIB ARREST Trial Expanded To China -
06/07/16 07:18 AMGalmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China - [at noodls] - TEL AVIV, Israel, June 7, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
06/04/16 09:39 PMGalmed Pharmaceuticals Ltd (GLMD) Receives “Buy” Rating from HC Wainwright - Let Me Know About This
06/03/16 10:27 PMMaxim Group Reiterates Buy Rating for Galmed Pharmaceuticals Ltd (GLMD) - Let Me Know About This
06/02/16 04:27 PMGalmed Pharmaceuticals Ltd. (GLMD) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Galmed Pharmaceuticals Ltd. (GLMD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Galmed Pharmaceuticals Ltd. (GLMD). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Stock Rating ReviewThe Postall 3 news articles »
06/01/16 07:23 AMGalmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial - [at noodls] - TEL AVIV, Israel, June 1, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
05/30/16 10:41 PMStock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - HNN - Stock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Galmed Pharmaceuticals Ltd.and more »
05/30/16 10:41 PMStock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - HNN - Stock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Galmed Pharmaceuticals Ltd.and more »
05/27/16 11:42 AMCould Galmed Pharmaceuticals Ltd Crash Even More? The Stock Had Another Big Decline Today - Wall Street Hints and News - Could Galmed Pharmaceuticals Ltd Crash Even More? The Stock Had Another Big Decline TodayWall Street Hints and NewsThe stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is a huge mover today! The stock decreased 6.46% or $0.28 on May 26, hitting $4.12. About 61,604 shares traded hands or 287.64% up from the average. Galmed Pharmaceuticals Ltd ...
05/16/16 07:32 AMGalmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - TEL AVIV, Israel, May 16, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
05/16/16 07:15 AMGalmed Pharmaceuticals reports 1Q loss -
05/09/16 07:30 AMGalmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016 - [PR Newswire] - TEL AVIV, Israel, May 9, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
05/03/16 07:30 AMMount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disea - [at noodls] - TEL AVIV, Israel, May 3, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
04/07/16 07:22 AMGalmed Pharmaceuticals to Hold a Symposium on Non-Invasive Diagnostics during the International Liver Congress in Spain - [at noodls] - TEL AVIV, Israel, April 7, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
04/05/16 01:54 PM[$$] Gilead Buy Could Bolster Galmed Valuation -
03/30/16 07:10 AMAramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease - [at noodls] - TEL AVIV, Israel, March 30, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
03/29/16 07:15 AMGalmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9% -
03/22/16 06:51 AMGalmed Pharmaceuticals reports 4Q loss -
03/07/16 07:30 AMGalmed Pharmaceuticals to Present at the ROTH Conference - [PR Newswire] - TEL AVIV, Israel, March 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that Josh Blacher, Chief Financial Officer, will present a company overview at the 28th Annual ROTH Conference in Orange County, California, on Monday, March 14, 2016 at 10:00 AM Pacific Standard Time. Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
03/01/16 07:30 AMGalmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study - [PR Newswire] - TEL AVIV, Israel, March 1, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has randomized the first patient in the ARRIVE Study (ARamcholTM for the Reversal of HIV-AssociatEd Lipodystrophy and NAFLD), a proof-of-concept clinical trial that will evaluate the safety and efficacy of AramacholTM in up to 50 patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease, or NAFLD. The ARRIVE Study is a randomized, double-blinded, allocation-concealed, placebo-controlled, proof-of-concept Phase IIa clinical trial, which is an investigator-initiated study, and is being conducted at the NAFLD Research Center, University of California San Diego by Professor Rohit Loomba.
02/26/16 09:52 AMChanges To Broker Targets On Galmed Pharmaceuticals Ltd. (GLMD) - Share Trading News - Changes To Broker Targets On Galmed Pharmaceuticals Ltd. (GLMD)Share Trading News04/01/2015 – Galmed Pharmaceuticals Ltd. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 24 price target on the stock. The share price of Galmed Pharmaceuticals Ltd. (GLMD) was down -8.37% during the last trading session, ...and more »
02/21/16 01:17 PMCan Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Move Higher On Charts? - Stocks Daily - Can Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Move Higher On Charts?Stocks DailyThe research group Zacks released a report as per which Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares can hit a high of $24 in the forthcoming fiscal. Zacks included several brokerages in the poll and thereafter defined a price target of $21.6 on ...Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Shorted Shares Increased 6.84% After Market SellingRiversideGazette.comall 2 news articles »

Social

About Galmed Pharmaceuticals

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLMD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.16
  • 50 Day Moving Average: $4.46
  • 200 Day Moving Average: $5.22
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $46.84M
  • Beta: 2.32
  • Current Year EPS Consensus Estimate: $-1.48 EPS
  • Next Year EPS Consensus Estimate: $-1.24 EPS
Additional Links:
Galmed Pharmaceuticals (NASDAQ:GLMD) Chart for Saturday, July, 23, 2016